(NASDAQ: XERS) Xeris Biopharma Holdings's forecast annual revenue growth rate of 21.42% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Xeris Biopharma Holdings's revenue in 2025 is $203,070,000.On average, 4 Wall Street analysts forecast XERS's revenue for 2025 to be $40,720,552,390, with the lowest XERS revenue forecast at $40,455,467,478, and the highest XERS revenue forecast at $41,456,078,356. On average, 5 Wall Street analysts forecast XERS's revenue for 2026 to be $47,794,409,474, with the lowest XERS revenue forecast at $37,946,243,278, and the highest XERS revenue forecast at $52,462,798,008.
In 2027, XERS is forecast to generate $56,171,523,740 in revenue, with the lowest revenue forecast at $46,536,102,811 and the highest revenue forecast at $63,700,427,863.